Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma|Toripalimab|Recurrent Nasopharyngeal Squamous Cell Carcinoma
DRUG: Toripalimab
Overall survival, Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up., 2 years
Progress-free survival (PFS), Defined from date of randomization to date of first documentation of progression or death due to any cause., 2 years|Objective Response Rate （ORR）, An objective response is defined as either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI)., After the completion of the PD-1 antibody and chemoradiotherapy treatment|Incidence rate of adverse events (AEs), Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0, 2 years|Change of QoL (quality of life), QoL scores were assessed by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) before radiotherapy, at the end of radiotherapy, at 12 months after radiotherapy., 1 year
This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.